First Horizon Advisors Inc. Has $425,000 Holdings in Sanofi (NASDAQ:SNY)

First Horizon Advisors Inc. increased its holdings in Sanofi (NASDAQ:SNY) by 15.6% in the third quarter, Holdings Channel reports. The institutional investor owned 7,375 shares of the company’s stock after buying an additional 998 shares during the period. First Horizon Advisors Inc.’s holdings in Sanofi were worth $425,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in SNY. POM Investment Strategies LLC acquired a new stake in Sanofi during the second quarter worth about $25,000. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi during the 3rd quarter worth approximately $29,000. Concord Wealth Partners increased its stake in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the last quarter. Arrow Financial Corp acquired a new position in Sanofi during the second quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC lifted its stake in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SNY. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus raised their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

Shares of SNY stock opened at $48.28 on Friday. The business’s 50-day moving average price is $53.70 and its 200-day moving average price is $52.15. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $122.53 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.55 EPS. Equities research analysts forecast that Sanofi will post 4.29 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.